Femasys Wins FDA Approval Pathway for Non-Surgical Contraceptive Device

The U.S. Food and Drug Administration on Wednesday approved a modular premarket approval application pathway for FemBloc, a non-surgical permanent contraception technology.

Femasys Inc. announced this regulatory milestone for its investigational contraceptive device.

Office-Based Alternative to Surgical Sterilization

FemBloc is a first-of-its-kind permanent contraception option, specifically designed for use in a standard obstetrics and gynecology office setting. During the procedure, physicians use a patented delivery system to place a proprietary polymer blend directly into both fallopian tubes.

After insertion, the polymer safely degrades and promotes the growth of natural scar tissue. This tissue eventually forms a permanent blockage, effectively occluding the fallopian tubes and preventing pregnancy.

Unlike traditional surgical sterilization methods, the FemBloc procedure requires no anesthesia, surgical incisions, or postoperative recovery time.

This non-surgical approach offers women a highly convenient and more affordable contraception option.

Additionally, the in-office treatment allows patients to completely avoid the various health complications and risks typically associated with invasive procedures.

Kathy Lee-Sepsick, CEO and founder of Femasys, stated: "FDA approval of the modular PMA pathway provides a clear and efficient framework for advancing FemBloc toward U.S. approval, allowing key sections of the submission to be reviewed by the FDA ahead of the final clinical data."

Technical Analysis

Femasys stock is currently trading below all key moving averages, indicating a bearish trend. The 20-day simple moving average is 5.9% below the stock price, while the 50-day simple moving average is 24.9% below the stock price, suggesting traders should exercise caution as the stock struggles to gain upward momentum.

The relative strength index is currently at 40.13, sitting in neutral territory. This level indicates no strong buying or selling pressure at present, leaving the stock vulnerable to further declines if momentum does not shift.

The MACD is above its signal line, indicating bullish momentum despite the overall bearish trend. This could signal the possibility of a short-term rebound, but traders should remain vigilant given the longer-term downtrend.

Currently, there are no clear support or resistance levels for Femasys Inc. stock, making it challenging to identify definitive entry or exit points. If the stock approaches previous highs or lows, its reaction could signal either trend continuation or reversal.

Femasys stock has not recently experienced a golden cross or death cross, but the current positioning of moving averages reflects a bearish long-term trend. The 50-day simple moving average is below the 200-day simple moving average, reinforcing the view that traders should remain cautious about long-term positions.

Over the past 12 months, Femasys stock has experienced a significant decline of 81.69%. This steep drop highlights the challenges facing the company, suggesting traders should be wary of potential further declines unless a strong reversal pattern emerges.

FEMY Price Action: As of Wednesday's writing, Femasys stock was up 24.09% at $2.73. The stock is trading near its 52-week low of $2.02.